Redcliffe Lifetech IncWinter 2021Active☆Watch⊞Compare

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Redcliffe Lifetech Inc is one of 233 Medical Devices companies tracked from WILMINGTON, DL, India; Gurugram, HR, India; Noida, UP, India, on record since 2021. By capital raised it ranks among the largest (ahead of 94% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

Redcliffe Labs is India's Largest Omni-channel Diagnostics platform

Redcliffe Labs (a unit of Redcliffe Lifetech Inc) provides diagnostics with a comprehensive portfolio approach both with routine and specialised test menus with advanced testing labs all over India. Its digital first approach with on-demand 1-hour home collection and same day report is disrupting the way diagnostics is delivered today and thus is the fastest growing in India. Redcliffe Labs is providing 3500+ tests across its wide network of labs and collection centres. The company has served about millions of Indians and is processing more than 250K+ test parameters daily. The test portfolio is very wide including routine pathology tests, advanced genetic screening, research-based DNA tests in reproductive health, cancer and wellness/fitness. The easy to interpret smart reports provide key health check-points, which can help in diagnosing and treating both chronic and acute diseases on time. Redcliffe Labs has pioneered Drone technology adoption in the diagnostic sector by opening up the first commercial corridor from Uttarkashi to Dehradun. The company currently has 30+ labs and 700+ authorised collection centres in more than 120 cities across India. Redcliffe's vision is to provide world-class diagnostic services to people across the Indian sub-continent in an affordable manner.

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Round size and date are reported; the stage label is inferred from round size (latest is Series C — a $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the medical devices sector profile. Directional, not a quoted figure.

Benchmarked against 233 companies in Medical Devices. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 94% of sector peers (real $). Modeled value above 99% of peers (estimate).

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful.

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

1. Series C$46.9M2022-01-10
   • First recorded raise — entered as Series C.
   • 15 investors on this round.
2. Series C$46.9M2022-01-10
   • Filed alongside the prior round (same month) — likely a tranche or amendment.
   • Round roughly the size of the prior one.
   • Revenue band moved $5M–$25M → No revenue.
   • 15 investors on this round.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

Redcliffe Lifetech Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Redcliffe Lifetech Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Redcliffe Lifetech Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.